AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Oral AZD8165 After Single Oral Ascending Doses in Healthy Male Subjects
- First Posted Date
- 2010-06-25
- Last Posted Date
- 2010-09-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 9
- Registration Number
- NCT01150812
- Locations
- 🇺🇸
Research Site, Overland Park, Kansas, United States
ATEM (Alvesco Non-interventional Study)
- First Posted Date
- 2010-06-22
- Last Posted Date
- 2016-12-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 400
- Registration Number
- NCT01147224
- Locations
- 🇦🇹
Nycomed Pharma GmbH, Zwettl, Austria
Study Evaluating Effect of Esomeprazole, Omeprazole or Lansoprazole on the Pharmacodynamics (PD) and Pharmacokinetics (PK) of Clopidogrel
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2010-06-22
- Last Posted Date
- 2011-06-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 149
- Registration Number
- NCT01147588
- Locations
- 🇺🇸
Research Site, Overland Park, Kansas, United States
To Investigate the Safety, Tolerability and Pharmacokinetics of AZD2516 After Multiple Dosing in Healthy Volunteers
Phase 1
Completed
- Conditions
- Part A Healthy Young Males and Non-fertile Female Volunteers Aged 20 to 45 Years.Part B Healthy Young Males and Non-fertile Female Volunteers Aged 20 to 45 and Elderly Volunteers Aged 60 to 80
- Interventions
- Drug: Placebo
- First Posted Date
- 2010-06-22
- Last Posted Date
- 2011-02-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 6
- Registration Number
- NCT01148095
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Single Oral Dose of 60 mg [14C]AZD9668 in Healthy Male Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: [C14]AZD9668
- First Posted Date
- 2010-06-22
- Last Posted Date
- 2010-12-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 4
- Registration Number
- NCT01147549
- Locations
- 🇬🇧
Research Site, London, United Kingdom
An Investigation of the Past 10 Yrs Health Care for Primary Care Patients With Chronic Obstructive Pulmonary Disease
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- First Posted Date
- 2010-06-17
- Last Posted Date
- 2014-06-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 27394
- Registration Number
- NCT01146392
- Locations
- 🇸🇪
Research Site, Uppsala, Sweden
6-week Study Treatment to Evaluate the Safety and Effectiveness of AZD2066 in Patients With Major Depressive Disorder
Phase 2
Terminated
- Conditions
- Major Depressive Disorder
- Interventions
- First Posted Date
- 2010-06-17
- Last Posted Date
- 2012-10-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 131
- Registration Number
- NCT01145755
- Locations
- 🇺🇸
Research Site, Seattle, Washington, United States
To Investigate the Safety and Tolerability of TC-5214 Following Oral Administration of Multiple Doses for up to 8 Days
- First Posted Date
- 2010-06-17
- Last Posted Date
- 2010-12-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 72
- Registration Number
- NCT01145768
- Locations
- 🇺🇸
Research Site, Overland Park, Kansas, United States
A Study to Compare the Efficacy and Safety of 2 Dosing Regimens of IV Infusions of AZD9773 (CytoFab™) With Placebo in Adult Patients With Severe Sepsis and/or Septic Shock
- First Posted Date
- 2010-06-16
- Last Posted Date
- 2014-10-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 300
- Registration Number
- NCT01145560
- Locations
- 🇪🇸
Research Site, Madrid, Spain
A Study to Assess Safety,and Tolerability of 2 Doses of AZD9773 (CytoFab™) in Japanese With Severe Sepsis/Septic Shock
- First Posted Date
- 2010-06-15
- Last Posted Date
- 2014-10-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 20
- Registration Number
- NCT01144624
- Locations
- 🇯🇵
Research Site, Osaka, Japan